Do CRP levels predict severity in COVID-19 hospitalized Egyptian patients?

Moneer, Mayada; Fouad, Shaimaa H; Allam, Mohamed Farouk; Taha, Sara; Okba, Ahmed Ashraf; Hosny, Amr; El-Moussely, Lamiaa M.; Roman, Sylvia Wefky

doi:10.21608/mid.2022.129490.1264

Cited by 2 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regard CRP level at the day of admission (CRP 1) in this research, there was high statistical significant difference between its levels (Median (IQR)) in moderate and severe group (58 (52 -89 mg/L) versus 137.5 (88 -184.5) mg/L respectively). This finding was in agreement with Moneer et al (17) who revealed that Patients showing a mean (±SD) of CRP 60.17 ±92.83 mg/L were patients regarded as moderate COVID-19 patients, while the mean (±SD) CRP level of 91.29 ±81.96 mg/L was present in severe cases with high statistical difference between them. Lentner et al (19) , found that the higher the CRP level in patients, the greater the severity of COVID-19 cases.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Exhaled Carbon Monoxide as a Marker of Inflammation in Hospitalized COVID-19 Patients

Elgendy¹,

Samra²,

Tawfik³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a virus that is quickly spreading and has heterogeneous clinical features. Early identification of prognostic variables is necessary to coordinate treatment plans and accurately determine patient severity. Objectives: The aim of the current work was to evaluate the possible value of exhaled carbon monoxide (CO) as a marker of inflammation in different severity categories of hospitalized COVID-19 patients. Patients and Methods: A prospective cohort study was conducted on 39 confirmed COVID-19 nonsmoker patients who admitted to isolation unit at Zagazig University isolation hospital from March 2021 to February 2022. They were divided into two groups: Moderate COVID-19 and severe COVID-19. Exhaled carbon monoxide (eCO) was measured on admission (day 1) and after seven days (day 7). Results: It was revealed that there was high statistically significant difference between the studied groups regarding eCO at day one and seven (the level was significantly higher among severe group) (p≤0.001). Also, there were high significant positive correlations between eCO and CRP level in both moderate and severe groups through day one and seven (p≤0.001). Conclusion: It could be concluded that exhaled CO analysis can be viewed as a noninvasive inflammatory marker for determining the level and severity of inflammation as well as forecasting the prognosis of COVID-19 patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Male patients were the majority in both studied groups. This agreed with Li and colleagues (16) and Moneer et al (17) who studied the epidemiologic data of the confirmed COVID-19 patients. Sex hormones from men and women have different effects on the immune system in the present disease.…”

Section: Discussionsupporting

confidence: 90%

Exhaled Carbon Monoxide as a Marker of Inflammation in Hospitalized COVID-19 Patients

Elgendy¹,

Samra²,

Tawfik³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, Mayada Moneer et al . [ 8 ] concluded that serum CRP is a simple and effective laboratory marker for identifying patients at risk of developing a severe form of COVID-19. In a study by Gao Y et al .…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, Wei Chen et al [7] found a direct association between the extent of severity of CT infiltration and the rising level of CRP regardless of patient age and lymphocyte count. Moreover, Mayada Moneer et al [8] concluded that serum CRP is a simple and effective laboratory marker for identifying patients at risk of developing a severe form of COVID-19. In a study by Gao Y et al [9], an average CRP level of 39.4 mg/L was detected in patients with severe COVID-19 infection, while patients with mild infection had a CRP level of 18.8 mg/L, which closely aligns with the findings of our current study.…”

Section: Discussionmentioning

confidence: 99%

Assessment of C-reactive protein levels as an indicator for lung infiltrates in patients with COVID-19 pneumonia

Kabil,

Atef,

Eid

et al. 2023

JMedLife

View full text Add to dashboard Cite

Lung infiltrates are frequently observed in patients with COVID-19 infection and require specialized management. Identifying reliable laboratory parameters to reduce the need for chest CT scans in non-desaturation patients is of great interest. This study aimed to investigate the potential of C-reactive protein (CRP) as an indicator to identify the presence of lung infiltrates in early COVID-19 infection. The study was conducted at Al-Azhar University hospitals from May 2021 to March 2022 and included 210 patients with COVID-19 infection confirmed by positive PCR, all of whom were previously healthy, non-smokers, and non-hypoxemic. CRP levels were assessed and correlated with lung infiltrates observed in CT chest examinations. The mean value of CRP was 40.3±14.3 mg/L in males and 36.6±15.2 mg/L among females. One hundred sixty-two patients had pneumonic infiltrates, while 48 had no infiltrates. The mean value of CRP was 45.02±10.2 mg/L in patients with radiological infiltrates and 18.8±7.8 mg/L in patients without radiological infiltrates. Based on our findings, a CRP value greater than 29.8 mg/L was suggested as a cut-off value to indicate the presence of lung infiltrates. CRP is a simple laboratory marker that, at certain limits, may point to the presence of pneumonic infiltrates in early non-hypoxemic patients with COVID-19 infection.

show abstract

Do CRP levels predict severity in COVID-19 hospitalized Egyptian patients?

Cited by 2 publications

References 39 publications

Exhaled Carbon Monoxide as a Marker of Inflammation in Hospitalized COVID-19 Patients

Exhaled Carbon Monoxide as a Marker of Inflammation in Hospitalized COVID-19 Patients

Assessment of C-reactive protein levels as an indicator for lung infiltrates in patients with COVID-19 pneumonia

Contact Info

Product

Resources

About